Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy
Open Access
Abstract
Large-scale assays, such as microarrays, next-generation sequencing and various “omics” technologies, have explored multiple aspects of the immune response following virus infection, often from a public health perspective. Yet a lack of similar data exists for monitoring immune engagement during oncolytic virus immunotherapy (OVIT) in the cancer setting. Tracking immune signatures at the tumour site can create a snapshot or longitudinally analyse immune cell activation, infiltration and functionality within global populations or individual cells. Mapping immune changes over the course of oncolytic biotherapy—from initial infection to tumour stabilisation/regression through to long-term cure or escape/relapse—has the potential to generate important therapeutic insights around virus-host interactions. Further, correlating such immune signatures with specific tumour outcomes has significant value for guiding the development of novel oncolytic virus immunotherapy strategies. Here, we provide insights for OVIT from large-scale analyses of immune populations in the infection, vaccination and immunotherapy setting. We analyse several approaches to manipulating immune engagement during OVIT. We further explore immunocentric changes in the tumour tissue following immunotherapy, and compile several immune signatures of therapeutic success. Ultimately, we highlight clinically relevant large-scale approaches with the potential to strengthen future oncolytic strategies to optimally engage the immune system.Keywords
Funding Information
- Ontario Institute for Cancer Research
- Canada Foundation for Innovation
- Angels of Hope
- Ottawa Regional Cancer Foundation
- Terry Fox Research Institute
This publication has 83 references indexed in Scilit:
- Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cellsJournal of Experimental Medicine, 2015
- High-dimensional analysis of the murine myeloid cell systemNature Immunology, 2014
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade ImmunotherapyScience Translational Medicine, 2014
- Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment StrategiesMolecular Therapy, 2014
- From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against CancerPLOS Pathogens, 2014
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccinesOncoImmunology, 2013
- Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell TransferCancer Research, 2012
- Oncolytic Viruses for Induction of Anti-Tumor ImmunityCurrent Pharmaceutical Biotechnology, 2012
- A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus ErythematosusImmunity, 2008
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003